Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer

Overview

This is a multicenter retrospective cohort of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)). The objective is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives.

This study is part of a broader project (CAMISS study), which also includes one prospective cohort (CAMISS Prospective cohort – Identifier in ClinicalTrials.gov: NCT02439554).

Full Title of Study: “CAMISS Retrospective Cohort – Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 30, 2014

Detailed Description

The general objective for this study is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives.

The cohort has information of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a breast cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)).

Expected results: Nowadays there are no results of cohort analysis of the diagnostic process of care that integrates all those different aspects. This study will complement the evaluation of population screening, specifically the interval cancer and the impact on survival and disease-free period taking into account relevant variables like breast density, tumor phenotype, clinical complications, readmissions, and the surgical approach.

This study is part of a broader project (CAMISS study) coordinated by the Evaluation of Health Services of Epidemiology and Public Health Group, which consists of two cohorts of women diagnosed with breast cancer: a prospective cohort (n=2,040 incident cases of breast cancer diagnosed in 18 hospitals of 5 Spanish regions) (Identifier in ClinicalTrials.gov: NCT02439554) and a retrospective cohort of screened women diagnosed with breast cancer between 2000 and 2009 in two Spanish regions (n=1,086).

The general objective of the CAMISS study is to evaluate different aspects of health care received by patients with breast cancer like the diagnostic process, treatment, complications, survival, costs and quality of life to provide information to improve the effectiveness and cost-effectiveness of interventions, reduce variability, have better predictive rules and increase the quality of life.

Interventions

  • Procedure: Mode of detection: Cancer detected at screening
    • Cancers detected as a result of screening mammograms.
  • Procedure: Mode of detection: Interval cancer
    • Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)

Arms, Groups and Cohorts

  • Screened women with breast cancer

Clinical Trial Outcome Measures

Primary Measures

  • Mortality
    • Time Frame: From date of cancer diagnosis until the date of death from any cause, assessed up to 14 years
    • Death from any cause

Secondary Measures

  • Recurrences and second breast neoplasms
    • Time Frame: From date of cancer diagnosis until the date of the first recurrence or second breast neoplasm, whichever came first, assessed up to 14 years
  • Treatment-related complications
    • Time Frame: From the date of surgery until the end of follow-up, assessed up to 14 years.
  • Readmissions to hospital for reasons related to breast cancer
    • Time Frame: From the date of surgery until the end of follow-up, assessed up to 14 years.

Participating in This Clinical Trial

Inclusion Criteria

  • Women aged between 50 to 69 years with invasive or in situ breast cancer.

Exclusion Criteria

  • Women diagnosed with lobular carcinoma in situ.

Gender Eligibility: Female

Women participating at screening

Minimum Age: 50 Years

Maximum Age: 69 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Parc de Salut Mar
  • Collaborator
    • Fondo de Investigacion Sanitaria
  • Provider of Information About this Clinical Study
    • Principal Investigator: Maria Sala, MD, PhD – Parc de Salut Mar

Citations Reporting on Results

Romero A, Torà-Rocamora I, Baré M, Barata T, Domingo L, Ferrer J, Torà N, Comas M, Merenciano C, Macià F, Castells X, Sala M; CAMISS Study Group. Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs. BMC Cancer. 2016 Sep 15;16(1):735. doi: 10.1186/s12885-016-2768-1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.